DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
about
New and emerging factors in tumorigenesis: an overviewNext-generation sequencing to guide cancer therapyIDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemiaIncreasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognitionClinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicEarly B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemiaImpact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients.The effects of chromatin organization on variation in mutation rates in the genome.DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 PatientsCharacteristics, clinical outcome, and prognostic significance of IDH mutations in AMLDNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemiaIDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progressionGenomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcomeSomatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotypeThe Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.Isocitrate dehydrogenase mutations in myeloid malignancies.Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.Zebrafish Discoveries in Cancer Epigenetics.Epigenetic alterations in acute myeloid leukemias.Pan-cancer patterns of DNA methylation.Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.Genetic alterations of DNA methylation machinery in human diseases.Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia.Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse.Short-Circuiting Gene Regulatory Networks: Origins of B Cell LymphomaDNA methylation profiles in cancer diagnosis and therapeutics.Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.Frontline treatment of acute myeloid leukemia in adults.IDH mutations in cancer and progress toward development of targeted therapeutics.Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.
P2860
Q26801253-F5ACC655-0099-4E80-B8B1-F0431530B6CCQ26801946-214CCC1E-3657-4448-8882-0962E0E646CCQ28066926-8C75FDDA-803F-44DE-8E7C-CC7908E13183Q30235355-460B77B4-945D-4278-826C-278520A1A567Q33435980-55528586-8CFB-40A1-B423-071C3A81A0C9Q33712307-D69D62DF-08F4-4EEF-8A2B-EC12FDC93A2DQ33761979-BC1FA03B-7966-4DC3-80B3-0F6613F7FB7DQ34340438-1E14CF61-A229-48FD-A878-B98C356130AEQ34607312-D6A092DF-647D-45E4-A340-84BAD6A76296Q34817365-A533862E-025B-43DD-9D40-EB9AFBD5F780Q35030109-E404168D-3594-4208-B124-C8D696E14162Q35646130-03EABC99-D798-48D4-A43F-FADDBEDCA418Q35806875-26F13616-D29A-4A90-B143-14FEA3FDA017Q35845235-173D18AC-FA7E-40ED-84D8-D82490687EEEQ36009675-5091746F-A5B1-423C-83DF-1E06890F619FQ36181742-8F7234AA-374C-4038-BF84-D44C765BA59FQ36442530-3A29588C-BA01-45C6-8B6A-A69A02823CDDQ36522731-1FD9C58D-BF0E-4A27-A900-95280E7DF7AEQ37017110-F024E0FE-C288-482C-AFCB-1027457D6387Q37216267-6F45CDDC-F620-4752-8868-C8E32C3074D4Q37221579-46695124-63DA-4F66-BBF3-8E5774FC9763Q37327786-CD20026C-3EFF-4983-8C7E-20ECDABCAE64Q37432049-D8893F6C-7B8A-44DE-B25C-A0FDD1E4891BQ37443338-5C27E7CF-0E11-4C37-9CF9-5D6C88815F83Q37625630-AE5E8703-767B-44A4-A949-B488EAD83B1BQ37645063-D3BF3154-02F6-4037-BC71-1B9C5884477AQ37648114-7CFBBDB2-EE12-4C86-A538-F0127313B93DQ37651410-12E53539-1899-4B14-B550-82B3D1D6690FQ38264968-42F7AB93-331D-493A-9414-5D06FBFFEE99Q38282894-306E3A0F-CFDD-4775-92D4-E4F4FAB6BD37Q38379074-9AEEC584-A02D-4E51-8A64-A319E31A5BD9Q38459846-00ABE6E0-DC9A-4D67-94BA-3DF485CFCF46Q38509706-1C53FE80-8459-4DCC-BB68-3BD1C4CE8619Q38611326-41AFC457-2B4A-4492-ACF8-F75B4DF3362CQ38646971-E3B79192-4F5B-48B4-B05C-EF55E326C067Q38650593-90AD45D6-300F-4A63-9B79-D6E27A163F41Q38694866-C7160C95-FABB-492B-B0DF-BBC09F54C572Q38767583-6C7596E8-C1AF-423B-BD8F-669C7533B6B3Q38785528-5C9560D1-6CE4-4F22-8B36-3CDA9483D7BFQ38860767-EF11BB48-45A4-4F8D-9B62-2872BE0C2E4C
P2860
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@ast
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@en
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@nl
type
label
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@ast
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@en
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@nl
prefLabel
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@ast
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@en
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@nl
P2093
P2860
P356
P1433
P1476
DNMT3A and IDH mutations in ac ...... potential treatment strategies
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2014.124
P577
2014-04-04T00:00:00Z
P5875
P6179
1035382728